PBM (PBM) Stock Price & Analysis
PBM (PBM) rose 4.61% to USD 2.95 as of July 25, 2026 at 10:43 UTC, according to Nexqual real-time market data.
PBM last closed at USD 2.82; the session ranged USD 2.8–3 on volume of 39,032 shares. Market capitalization is —, with a 52-week range of USD 1.92–468.36 (NCM). Source: Nexqual, July 25, 2026 at 10:43 UTC.
Key Statistics (as of July 25, 2026 at 10:43 UTC)
| Price | USD 2.95 |
|---|---|
| Change | ▲ 4.61% (up) |
| Previous Close | USD 2.82 |
| Open | USD 2.94 |
| Day Range | USD 2.8 – 3 |
| 52-Week Range | USD 1.92 – 468.36 |
| Volume | 39,032 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (PBM)
Nexqual's technical model rates PBM "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 10:43 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 43.88 (neutral) |
| vs SMA50 | Below (USD 3.47) |
| MACD | -0.14 (negative) |
Analyst Ratings (PBM)
Wall Street analysts rate PBM "None", per Nexqual as of July 25, 2026 at 10:43 UTC.
| Consensus Rating | None |
|---|
Earnings (PBM)
Source: Nexqual, July 25, 2026 at 10:43 UTC.
Financials & Fundamentals (PBM)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -58.62% |
| Current Ratio | 14.62 |
| Total Cash | $7.44M |
| Total Debt | $0 |
| Free Cash Flow | $-4.96M |
Source: Nexqual, July 25, 2026 at 10:43 UTC.
Financial Health Score (PBM)
Nexqual rates PBM's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 10:43 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — $7M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$8M |
| Efficiency | Critical — ROE -59%, ROA -31.3% |
Ownership (PBM)
| Insider Ownership | +2.97% |
|---|---|
| Institutional Ownership | +4.02% |
| Float | 2.61M |
| Short % of Float | +1.15% |
Source: Nexqual, July 25, 2026 at 10:43 UTC.
Leadership (PBM)
PBM is led by Jody Aufrichtig (age 51), Co-Founder, Executive Chairman & CEO, per Nexqual as of July 25, 2026 at 10:43 UTC.
| Co-Founder, Executive Chairman & CEO | Jody Aufrichtig (age 51) |
|---|---|
| CFO & Director | Warwick Ron Corden-Lloyd (age 45) |
Major Backers & Investors (PBM)
Notable institutional backers of PBM include Parallel Advisors, LLC, AdvisorShares Trust-AdvisorShares Psychedelics ETF, according to Nexqual as of July 25, 2026 at 10:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Parallel Advisors, LLC | 3.97% |
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 3.2% |
Source: Nexqual, July 25, 2026 at 10:43 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RENX | RenX Enterprises Corp. | USD 2 | ▲ 3.09% |
| MIRA | MIRA Pharmaceuticals, Inc. | USD 0.88 | ▼ 4.98% |
| GXAI | Gaxos.ai Inc. | USD 1.06 | ▼ 0.93% |
| CMND | Clearmind Medicine Inc. | USD 1.61 | ▼ 3.59% |
| CERO | CERo Therapeutics Holdings, Inc | USD 0.01 | ▼ 9.09% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 10:43 UTC. This page is informational and not investment advice.